Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in etiology

Acute lymphoblastic leukemia (ALL) afflicts 2,250 children (0-14 years) diagnosed annually in the USA.[1][1] Modern treatment regimens cure approximately 90% of those affected, but survivors suffer from long-term sequelae.[2][2] Epidemiological evidence regarding the occurrence of ALL points to